Prospective randomized Phase II trial in nutritional support for autologous PBSCT Non-synbiotics vs Synbiotics

Authors
Category Primary study
JournalUMIN Clinical Trials Registry
Year 2008
INTERVENTION: Intervention: Use of GFO and lactobacillus in patients who receive autologous PBSCT Standard : No Use of GFO and lactobacillus in patients who receive autologous PBSCT CONDITION: malignant lymphoma or multiple myeloma PRIMARY OUTCOME: Probability of more than grade 3 intestinal regimen related toxicity SECONDARY OUTCOME: (1) 1‐year overall survival and event‐free survival; (2) Regimen related toxicity except intestinal toxicity; (3) Engraftment; (4) Infectious diseases; (5) Duration of TPN; (6) Dose and duration of intravenous morphine; (7) Dose of insulin; (8) Hyperglycemia and hypoglycemia; (9) DAO activity INCLUSION CRITERIA: (1) Malignant lymphoma or multiple myeloma who can be candidate for autologous PBSCT (2) 17
Epistemonikos ID: 32cd00c8ec4905a162cf26cb67f6e78333629e32
First added on: Aug 21, 2024